Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries PepGen Inc. - Common Stock (NQ: PEPG ) 8.880 +0.140 (+1.60%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 26,973 Open 8.730 Bid (Size) 8.830 (1) Ask (Size) 8.880 (1) Prev. Close 8.740 Today's Range 8.632 - 8.950 52wk Range 3.720 - 19.30 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society October 08, 2024 From PepGen Inc. Via Business Wire Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher September 30, 2024 Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy Via MarketBeat Exposures Product Safety Performance YTD +25.25% +25.25% 1 Month -2.63% -2.63% 3 Month -46.28% -46.28% 6 Month -27.39% -27.39% 1 Year +63.84% +63.84% More News Read More PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors September 19, 2024 From PepGen Inc. Via Business Wire PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development August 20, 2024 From PepGen Inc. Via Business Wire PEPG Stock Earnings: PepGen Misses EPS for Q2 2024 August 08, 2024 Via InvestorPlace PEPG Stock Earnings: PepGen Beats EPS for Q1 2024 May 14, 2024 Via InvestorPlace PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development August 20, 2024 From PepGen Inc. Via Business Wire PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings August 11, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights August 08, 2024 From PepGen Inc. Via Business Wire PEPG Stock Earnings: PepGen Beats EPS for Q4 2023 March 06, 2024 Via InvestorPlace PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings August 02, 2024 From Bronstein, Gewirtz & Grossman, LLC Via Business Wire Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher July 31, 2024 Via Benzinga Dow Jumps Over 200 Points; Kraft Heinz Shares Gain After Q2 Earnings July 31, 2024 Via Benzinga Topics Stocks Exposures US Equities PEPG Investors Have Opportunity to Join PepGen Inc. Securities Fraud Investigation with the Schall Law Firm July 31, 2024 From The Schall Law Firm Via Business Wire PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy July 30, 2024 From PepGen Inc. Via Business Wire PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications July 02, 2024 From PepGen Inc. Via Business Wire PepGen Announces Executive Team Promotions June 11, 2024 From PepGen Inc. Via Business Wire PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights May 14, 2024 From PepGen Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Pre-Market Session April 12, 2024 Via Benzinga Insiders Buying GameStop And 2 Other Stocks April 10, 2024 Via Benzinga PepGen to Participate in Upcoming Investor Conferences March 13, 2024 From PepGen Inc. Via GlobeNewswire PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy March 13, 2024 From PepGen Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Intraday Session March 07, 2024 Via Benzinga PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments March 06, 2024 From PepGen Inc. Via GlobeNewswire PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy March 04, 2024 From PepGen Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
